1. Home
  2. ENZ vs IGC Comparison

ENZ vs IGC Comparison

Compare ENZ & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENZ
  • IGC
  • Stock Information
  • Founded
  • ENZ 1976
  • IGC 2005
  • Country
  • ENZ United States
  • IGC United States
  • Employees
  • ENZ N/A
  • IGC N/A
  • Industry
  • ENZ Medical Specialities
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENZ Health Care
  • IGC Health Care
  • Exchange
  • ENZ Nasdaq
  • IGC Nasdaq
  • Market Cap
  • ENZ 34.2M
  • IGC 29.4M
  • IPO Year
  • ENZ N/A
  • IGC N/A
  • Fundamental
  • Price
  • ENZ $0.56
  • IGC $0.31
  • Analyst Decision
  • ENZ
  • IGC Strong Buy
  • Analyst Count
  • ENZ 0
  • IGC 2
  • Target Price
  • ENZ N/A
  • IGC $3.75
  • AVG Volume (30 Days)
  • ENZ 125.9K
  • IGC 367.3K
  • Earning Date
  • ENZ 03-12-2025
  • IGC 02-18-2025
  • Dividend Yield
  • ENZ N/A
  • IGC N/A
  • EPS Growth
  • ENZ N/A
  • IGC N/A
  • EPS
  • ENZ N/A
  • IGC N/A
  • Revenue
  • ENZ $30,314,000.00
  • IGC $1,183,000.00
  • Revenue This Year
  • ENZ N/A
  • IGC N/A
  • Revenue Next Year
  • ENZ N/A
  • IGC $13.38
  • P/E Ratio
  • ENZ N/A
  • IGC N/A
  • Revenue Growth
  • ENZ N/A
  • IGC N/A
  • 52 Week Low
  • ENZ $0.54
  • IGC $0.27
  • 52 Week High
  • ENZ $1.40
  • IGC $0.91
  • Technical
  • Relative Strength Index (RSI)
  • ENZ 28.08
  • IGC 35.18
  • Support Level
  • ENZ $0.56
  • IGC $0.31
  • Resistance Level
  • ENZ $0.69
  • IGC $0.33
  • Average True Range (ATR)
  • ENZ 0.03
  • IGC 0.02
  • MACD
  • ENZ 0.00
  • IGC -0.00
  • Stochastic Oscillator
  • ENZ 11.54
  • IGC 3.89

About ENZ Enzo Biochem Inc. ($0.01 Par Value)

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: